Agios Pharmaceuticals (AGIO) Income recognized in respect of BARDA — Quarterly & Annual

Screener

Income recognized in respect of BARDA at other companies

Odysight.aiODYS

-$12K-109%

EyePoint, Inc.EYPT

$0—

EyePoint, Inc.EYPT

$0—

Opko HealthOPK

$1.9M-55.8%

Inter ParfumsIPAR

$0—

WEC Energy GroupWEC

$31.4M+7,950%

Segments

By segment

Reportable Segment$30.35M+10.0%

Other financials

Income statement

Revenue$44.7M+259%

Gross profit$41.7M+288%

Operating income-$110.6M+13.0%

Net income-$100.7M+10.1%

EPS (diluted)-$1.69+12.4%

Balance sheet

Cash & equivalents$99.6M+23.2%

Total debt$31.2M-36.1%

Total equity$1.0B-25.1%

Total assets$1.1B-24.7%

Cash flow

Operating cash flow-$57.3M+25.7%

CapEx$1.2M+38.5%

Free cash flow-$58.5M+25.0%

Valuation

Market cap$1.93B-5.5%

Enterprise value$1.86B-7.4%

P/S19.6×-30.3×

Profitability

Gross margin92%+3.8pp

Operating margin-466.8%-173pp

Net margin-418.2%—

FCF margin-371.4%-143pp

Returns & leverage

Return on equity-34.3%—

Debt / equity0×0.0×

Current ratio10.2×-4.3×